Shopping Cart

INTRODUCTION

The influenza virus significantly impacts public health worldwide. It causes a highly contagious illness that disproportionately affects children and the older adults. Influenza (commonly called “flu”) is a powerful infectious disease that has caused significant outbreaks in the absence of vaccination.¹  

In the United States (U.S.), influenza remains a public health priority. Due to the high burden of disease, the Centers for Disease Control and Prevention (CDC) monitors influenza activity on a weekly basis and provides accurate surveillance data in the FluView and FluView Interactive report (https://www.cdc.gov/flu/weekly/fluviewinteractive.htm) using 5 distinct sources²:

1. Virologic surveillance
2. Outpatient illness surveillance
3. Summary of the geographic spread of influenza
4. Hospitalization surveillance
5. Mortality surveillance

This monitoring is performed in tandem with the World Health Organization (WHO), and the WHO’s FluNet tool serves a similar purpose to the CDC’s FluView: each week, FluNet monitors virological data and reports influenza statistics on a global scale by region or country.³ Tracking and reporting this information is crucial for monitoring the prevalence of certain strains of the influenza virus so that outbreaks may be addressed proactively and the appropriate influenza vaccination composition can be predicted for the upcoming season.

In the U.S., influenza infections generally begin to appear in October or November and flu activity lasts through the winter, often until March and sometimes later into the spring. Vaccination remains one of the most effective methods for avoiding infection from influenza. For the 2017-2018 influenza season, the influenza vaccine was estimated to provide 40% effectiveness against circulating influenza virus and to prevent more than 5.3 million illnesses, 2.6 million medical visits, and more than 85,000 hospitalizations due to infection.⁴ The 2017-2018 season was unique in that it affected all age groups—hospitalizations related to influenza were the highest since 2015 across all categories.⁴ The influenza vaccination is also shown to reduce pediatric deaths: over a 5-year period—from 2010 to 2014—vaccination was associated with a reduced risk of influenza-related death in patients aged 6 months through 17 years.⁵ Vaccine recommendations are very important in this population considering that 80% of all pediatric deaths that occurred due to influenza during the 2017-2018 influenza season were in unvaccinated children.⁴ Data further show that people who are infected with influenza virus despite vaccination appear to have reduced burden of disease compared to those who did not receive a vaccination. Similarly, in a study of patients across multiple age groups hospitalized with influenza, vaccinated patients benefitted from reduced risks of in-hospital death, decreased rates of intensive care unit admission, and shortened lengths of stay.⁶

PATHOPHYSIOLOGY OF INFLUENZA VIRUS

Influenza is an RNA virus that is categorized into 3 distinct types on the basis of antigen presentation: A, B, and C.⁷ Type A is the most virulent strain and is likely to cause more severe illness than the other types; it affects both humans and other animals—particularly birds.⁷ Type A virus affects all age groups equally and is identified by 2 subtypes: hemagglutinin and neuraminidase. Hemagglutinin (abbreviated H or HA) is a surface antigen that is responsible for virus attachment to cells, and neuraminidase (N or NA) is responsible for virus penetration into cells.⁷ Hemagglutinin and neuraminidase are further isolated into number-based subtypes, which represent the strain composition of the influenza virus (e.g., H3N2). Type B virus typically presents as milder disease upon infection and affects only humans. Type C virus is rarely isolated in humans.

Influenza virus strains are named on the basis of classifications using 5 pieces of information: virus type, geographic origin where it was first isolated, strain number, year of isolation, and virus subtype.⁷ Strains of the influenza virus change over time as a result of evolutionary pressures. The degree to which strains antigenically change is referred to as drift versus shift.⁷ Antigenic drifts can occur with any influenza strain and are often small mutations that may lead to a mismatch between the vaccine and the circulating strains. The drift and subsequent vaccine mismatch can result in an epidemic, which is defined as a stark increase in the number of cases of disease above what is expected in a given area.⁸ Antigenic shifts are more severe and occur with large changes in Type A strains such as a change in the subtype of hemagglutinin and/or neuraminidase. These significant changes can result in a pandemic, which is an epidemic spread over multiple areas and affecting a large number of people.⁸

The influenza virus is spread via respiratory droplets. The virus incubation period varies from person to person but usually ranges from 1 to 4 days. Approximately 50% of infected hosts will experience symptoms after this incubation period.⁷ The symptoms of flu, including myalgia, headache, cough, and rapid-onset fever, usually last 2 to 5 days. While healthy patients typically recover from influenza infection, the majority of significant complications associated with influenza are the result of secondary infection due to pneumonia that can result in death, particularly for older patients.⁷ Population-based influenza vaccination efforts not only help protect individuals from infection but also help to prevent the spread of illness to high-risk groups. Antiviral treatment options exist for patients infected with influenza virus but are beyond the scope of this monograph.

HISTORICAL IMPACT OF INFLUENZA

Historical antigenic shifts of the influenza virus have produced some of the deadliest patterns of infectious disease ever seen worldwide. These influenza pandemics serve as stark reminders of the impact of influenza in the absence of vaccination. Table 1 lists the most notable global pandemics of the past century.^1,9

Spanish influenza

The pandemic of 1918 (also known as “Spanish influenza”) reflected a significant change in the type A H1N1 virus. The antigenic changes combined with the inability to treat complications such as bacterial infection resulted in significant morbidity and mortality.¹ It is estimated that nearly one-third of the entire world’s population at the time—a total of nearly 500 million people—were infected with the virus and experienced symptoms of infection; approximately 50 million people died from infection with Spanish influenza.¹⁰ A unique feature of this virus was that deaths attributed to it were not distributed in a typical “u-shaped curve”: the virus of 1918 affected more than just young children and the elderly and was described with a “w-shaped curve” due to its propensity to affect significant numbers of young adults aged 15 to 34 years in addition to the young and the elderly.¹⁰ While advances in vaccination, antivirals/antibiotics, and preventive efforts have reduced the chance of a pandemic of this magnitude occurring again, it is estimated that a similar virus would kill nearly 100 million people today.¹⁰

Asian influenza

The H2N2 Asian influenza virus was a novel strain to which many populations had not been previously exposed.¹ The virus did not reach the levels of morbidity or mortality seen with the Spanish influenza pandemic, but it still had a significant impact on the world’s health: more than 1.1 million deaths were attributed to Asian influenza. The H2N2 virus affected populations in a more traditional “u-curve” than the Spanish influenza pandemic. The advent of laboratory isolation and delays in mortality related to the H2N2 virus reinforced the importance of immunization to prevent future outbreaks.¹¹

Hong Kong influenza

The Hong Kong influenza virus is notable for its representation of an antigenic shift from the H2N2 Asian influenza virus to the isolated H3N2 strain. This pandemic was responsible for nearly 2 million deaths from 1968 to 1970.^1,12 It affected different regions of the world at different times; changes in exposures were hypothesized to be due to previous exposure to the N2 strain that remained unchanged from the Asian influenza pandemic 10 years earlier.

Swine influenza

The most recent pandemic was caused by an H1N1 strain of influenza virus. Nearly 300,000 deaths worldwide were attributed to the respiratory and cardiovascular complications resulting from Swine influenza infection.⁹ Similar to Spanish influenza, the H1N1 virus disproportionately affected adolescents and young adults; adults older than 60 years of age had a potential previous exposure to the virus, which possibly lessened the rate of infection in this population during the subsequent exposure. This was the first pandemic that occurred in the 21^st century and it engendered a significant worldwide response. The response in the U.S. was noted to feature pharmacies and pharmacists as prominent points of vaccination as part of the disaster response.

INFLUENZA VACCINATION

The influenza virus was first isolated in 1933 and a live vaccine was developed a short time later.¹³ The first bivalent inactivated influenza vaccine (IIV) was developed in 1942; it contained a single A strain and a single B strain of influenza virus.¹³ The development of this vaccine was crucial to the discovery of antigenic drifts and shifts, since the vaccine’s effectiveness waned after initial development. Since 1973, the WHO has proactively released the predicted composition of influenza vaccines for each influenza season. The first trivalent vaccine (i.e., a vaccine containing 3 virus strains) was available in 1978.¹³ Now, most available vaccines are quadrivalent, which was first recommended as an option by the WHO in 2013.¹³ Table 2 summarizes the available influenza vaccines for the 2019-2020 season.¹⁴

Inactivated influenza vaccine

The most common type of influenza vaccine available in the U.S. and around the world is inactivated influenza vaccine (IIV). This type of vaccine is developed using a manufacturing process in which the predicted influenza viruses for a given season are injected into eggs and then grown over a period of days.¹⁵ The strains are isolated, sterilized, and tested prior to being administered to patients. This manufacturing process is the most common method of vaccine development to date. Notable for the 2019-2020 influenza season, only quadrivalent (IIV4) formulations of IIV are available outside of high dose or adjuvanted formulations of the influenza vaccine (Table 2).¹⁴

Cell culture-based inactivated influenza vaccine

The cell culture-based IIV (ccIIV) is developed in the same manner as the traditional IIV, but mammalian cells are used instead of traditional eggs.¹⁵ For the first 4 years of production, ccIIV started with a egg-grown candidate virus, but was replaced by a completely cell-grown candidate virus in 2016.¹⁶ The ccIIV is considered equipotent and efficacious to IIV and similar to other IIV vaccines is only available as a quadrivalent formulations in the 2019-2020 flu season (Table 2).¹⁴

Recombinant influenza vaccine

Recombinant influenza vaccine (RIV) is distinct from other types of vaccine, since eggs are not used in the manufacturing process. RIV is a modified version of the influenza virus that is designed to generate proteins that produce immunity to influenza in a similar manner to traditional IIVs but does not use an egg-based production process.¹⁵ RIV is appropriate for patients on the basis of individual preferences or vaccine availability, but RIV is only approved for adults aged 18 years or older.¹⁴ For the 2019-2020 influenza season, RIV4 contains three times the amount of antigen (45 μg) as standard IIV4 (15 μg)¹⁴ ; however, no preference for one vaccine formulation is preferred over another and comparative studies are discussed in more detail in the ‘Adults aged 65 years or older’ section below.

High-dose and adjuvanted inactivated influenza vaccines

Two influenza vaccines are specifically indicated for adults 65 years of age and older: high-dose IIV (HD-IIV3) and adjuvanted IIV (aIIV3).¹⁴ Both are only available in a trivalent formulation. HD-IIV3 (60 μg) showed increased efficacy for older adults compared to standard-dose influenza vaccines (IIV3) during the 2011-2012 and 2012-2013 influenza seasons.¹⁷ MF59 is an adjuvant included in a standard dose trivalent formulation (aIIV3; 15 μg) designed to produce a more robust immune response in older adults. Data continue to be inconclusive to recommend one vaccine product over another and comparative studies are discussed in more detail in the ‘Adults aged 65 years or older’ section below.

Live-attenuated influenza vaccine

LAIV has historically been a needle-free option for patients, particularly children, who do not have any contraindications to live vaccinations. The manufacturing process for LAIV is similar to that for IIV. LAIV3 was first approved back in 2003 and replaced by LAIV4 when recommended in the 2013-2014 season as an option for patients 2 to 49 years of age.¹⁸

Up to the 2014-2015 season, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that children older than 2 years of age should receive the live vaccine when available.¹⁹ However, during the 2016-2017 and 2017-2018 influenza seasons, ACIP recommended that LAIV4 not be used because the vaccine did not provide effective protection against circulating H1N1 influenza strains.^18,20 During the 2018-2019 influenza season, ACIP changed this recommendation, advising that LAIV4 should be an option for patients without a preferential recommendation against the vaccine given more recent efficacy date on an updated formulation.¹⁸ ACIP continues to monitor effectiveness data which supports the current decision to express no preference for any vaccine formulation during the 2019-2020 influenza season (RIV4, IIV4, or LAIV4) without a valid contraindication.¹⁴

Contraindications and precautions of influenza vaccine

All eligible patients who receive the influenza vaccine should be adequately screened for contraindications and precautions prior to vaccination. All influenza vaccines, regardless of the type or formulation, include consistent contraindications: (1) history of severe allergic reaction to any component of the vaccine or after previous dose of any influenza vaccine, and (2) anyone younger than 6 months of age.¹⁴ LAIV4 is also contraindicated in cases of immunosuppression, pregnancy, children 2 to 4 years of age with asthma (including parents who report a health care provider indicated that a wheezing episode had occurred in the past 12 months), receipt of an antiviral to treat influenza in the past 2 days, concomitant aspirin- or salicylate-containing therapy in children and adolescents, or close contacts of severely immunosuppressed persons who require protective environment.¹⁴ LAIV has additional precautions such as children with asthma aged 5 years or older and the presence of other chronic conditions worsened by influenza infection.¹⁴ Caution should be used with all influenza vaccines in any patient with moderate-to-severe acute illness with or without fever and/or a history of Guillain-Barré syndrome within 6 weeks of receipt of a previous influenza vaccine.

ACIP RECOMMENDATIONS FOR THE 2019-2020 INFLUENZA SEASON

For the 2019-2020 influenza season, between 162 and 169 million doses of vaccine are expected to be produced in the U.S.²¹ These projections represent consistency in production to the 169.1 million doses that were produced for the 2018-2019 season.²¹ It is expected that over 80% of the projected doses will be quadrivalent vaccines.²¹ Figure 1 lists the compositions of all influenza vaccines produced for the 2019-2020 season.¹⁴

The most significant changes for the 2019-2020 influenza season include the inclusion of two new A strains (H1N1 and H3N2) while the B strains stayed consistent in all trivalent and quadrivalent vaccines.¹⁴ There was one change to the recommended ages of administration of previously approved vaccines (summarized in Table 2) as well as a new pediatric dose for Fluzone Quadrivalent (IIV4) for children less than three years old. Consistent with 2018-2019, providers can continue to recommend any appropriate influenza vaccine where there is not a valid contraindication (IIV, RIV, or LAIV).^14,18

General recommendations

All patients older than 6 months of age without a valid contraindication should receive at least one influenza vaccination annually.¹⁴ When more than one influenza vaccine is available for patients, the ACIP does not recommend any one vaccine over another but pharmacists should ensure that patients are getting an age appropriate vaccine. Table 3 summarizes the ACIP recommendations for the 2019-2020 influenza season.¹⁴

Pregnancy

Influenza infection is potentially more severe for pregnant women and puts both mother and child at risk for negative health outcomes.²² Vaccination with IIV4 or RIV4 is safe and effective any time during pregnancy and offers benefits for both the mother and the child, who cannot be vaccinated until at least 6 months of age.²³ Studies have shown that influenza vaccines administered to the mother during pregnancy were more than 90% effective at reducing childhood hospitalizations for influenza during the infant’s first 6 months of life.²³  

Given live vaccinations are contraindicated in pregnancy, pharmacists and pharmacy technicians need to be vigilant to avoid recommending LAIV4 administration in pregnant patients in an effort to reduce unnecessary risks to the mother and the child. Clinicians and health care professionals should endorse inactivated formulations of the influenza vaccine (IIV4 or RIV4) for pregnant women.¹⁴

Children

Influenza infections disproportionately affect children, particularly those under the age of 5 years; influenza in this population increases the risk for hospitalization to a rate that is similar to that seen in older adults.²⁴ Both updates to the 2019-2020 influenza age and dosing recommendations involved children under 3 years of age: 1) Afluria Quadrivalent was approved for dosing in children aged 6 months or older; 2) ACIP recommended that patients 6 to 35 months of age can receive either the 0.25 mL or 0.5 mL dose of Fluzone Quadrivalent with no preference for one volume over another.¹⁴ Dosing remains the same for Fluarix Quadrivalent and FluLaval Quadrivalent (0.5 mL) and Afluria Quadrivalent is dosed with a volume of 0.25 mL.¹⁴ In states or territories where pharmacists and pharmacy technicians are allowed to vaccinate pediatric patients via protocol or medical order, special attention should be paid to the appropriate volume and dose based on the formulation and patient age.

In order to fully protect children from influenza, children aged 6 months to 8 years should continue to receive 2 vaccinations separated by at least 4 weeks in the first year that the child receives the vaccine.¹⁴ The first dose should be administered as soon as possible so the series can be completed prior to the start of influenza activity. A significant improvement in immune response is achieved in children under the age of 8 years with 2 vaccinations compared to a single vaccination.²⁵ Adherence to the second dose remains a difficult challenge due to provider and patient confusion, as well as the inconvenience of the follow-up visit for a second vaccine administration 4 weeks after the initial dose. Given the similarity of vaccine compositions in the past 5 years, the ACIP recommends that a patient aged 8 years or younger who has already received at least 2 total influenza vaccinations prior to July 1, 2019 does not need the second vaccination for the 2019-2020 influenza season. Figure 2 provides a flow chart of this decision-making process.¹⁴

Adults aged 65 years or older

Older adults, especially those with chronic diseases, are at high risk of complications secondary to infection from influenza. Both hospitalizations and death from influenza-related causes are significantly higher in older adults than in younger patients,²⁶ which reinforces the need for vaccination in older adults. HD-IIV3, aIIV3, and RIV4 have all been studied in comparison to SD-IIV3/4 and the HD-IIV3 has shown the most efficacy when compared to SD-IIV3 in older adults.¹⁷ Due to the limited data comparing HD-IIV3, aIIV3, and RIV4 to one another, ACIP does not state a preference for any vaccine formulation over another for older adults.¹⁴ If HD-IIV3 is not immediately available, pharmacists should not delay vaccination in older adults to wait for the formulation, because the risk of a missed vaccination opportunity is greater than the difference in benefit a patient may receive from a different formulation of the vaccine. Studies involving HD-IIV3, aIIV3, and RIV4 are ongoing and ACIP continues to monitor for future changes in influenza immunization recommendations for older adults.^14,17

Patients with egg allergies

Given the role of eggs in the production of IIV, special consideration should be given to patients with egg allergies prior to vaccination. An egg allergy alone is not a contraindication to vaccination and pharmacists should assess patients who present with egg allergies. If patients can eat lightly cooked eggs (e.g., over-easy, scrambled) without a reaction, they are unlikely to have a true allergy to eggs. However, patients who can eat egg-containing products, such as cake, could still have an egg allergy—tolerating egg containing food does not represent the absence of an egg allergy.¹⁴

ACIP recommends that patients who have only experienced hives from eggs can still receive any type of influenza vaccine.¹⁴ If the patient had a more serious reaction to eggs such as respiratory distress, angioedema, and/or lightheadedness, ACIP recommends that the patient receive the vaccine at an inpatient facility or another setting with access to acute medical care.¹⁴ Severe allergic reactions are a contraindication to subsequent influenza vaccine. While ACIP does not recommend one vaccine over another, RIV4 and ccIIV4 do not involve egg in the production process and ACIP notes that IIV production involves eggs and may pose a greater risk of anaphylaxis to patients with severe egg allergies¹⁴

Timing of influenza vaccination

The goal of influenza vaccination is to ensure that as much of the population is vaccinated prior to the onset of influenza season as possible. Since the onset and peak of each influenza season vary from year to year, as well as from location to location, vaccination should generally be offered by the end of October and continued until there is no influenza virus circulating or the vaccine supply has expired. Delaying vaccination could result in suboptimal protection in the case of an early peak to influenza season, as well as an increased risk that the patient will not return at a later date to receive the vaccination. The approximate time to develop a sufficient antibody response to the vaccine is 2 weeks.¹⁴  

The effectiveness of the influenza vaccine is estimated to last approximately 6 months after administration, but the response and duration of efficacy to the influenza immunization can vary with age and other patient-specific factors. Data showed that immunogenicity of the vaccine waned in patients who had low pre-vaccination titers and in adults older than 65 years.²⁸ Subsequent studies confirmed that the risk for influenza increases in adults and young children for each 2-week period after the initial vaccination.²⁹ There is no recommendation for a second vaccination, or booster dose, for adults and children older than 8 years of age who have already been vaccinated.

Vaccine storage

All vaccines should be stored under refrigeration at 36°F to 46°F (2°C to 8°C). No influenza vaccine needs to be frozen.¹⁴ Many pharmacists and technicians participate in off-site influenza clinics within their communities and should consult the specific package insert for each vaccine to ensure that the proper storage temperature is maintained and all storage requirements are adhered to for multi-dose and single-use vaccines when transported to other locations.¹⁴ All influenza vaccines produced for the 2019-2020 season will expire by June 30, 2020, but vaccines produced earlier in the season may expire prior to this date: no vaccine should be used past its expiration date.

INFLUENZA VACCINE MYTHS AND MISCONCEPTIONS

An extensive body of literature supports vaccination and its impacts on public health in fighting infectious diseases, including influenza. However, increasing numbers of patients are becoming skeptical about the effectiveness and safety of vaccines. A common misconception is the perceived link between autism and vaccines, especially the role of thimerosal, a preservative used in multi-dose influenza vaccines.

Wide-ranging literature supports the assertion that there is no link between vaccination and autism spectrum disorder (ASD). Specifically, patients with and without ASD were measured for exposure to vaccines on the basis of immune response in the first 2 years of life. Exposure to antigens from vaccinations was not associated with an increased risk for ASD at 3 months, 7 months, or 2 years of age.³⁰

Patients now have access to multiple sources of information regarding vaccination yet advances in technology and social media consistently expose patients to multiple perspectives on vaccination. Research evaluating opinions of influenza vaccination expressed on social media networks during the H1N1 outbreak confirms that patients who express opinions about vaccination, either positive or negative, on social media are less likely to share their views with those who express the opposite opinion.³¹ As patients continue to obtain more information through online networks, the role of pharmacists and pharmacy technicians in advocating for immunization takes on greater importance in the face of growing unsubstantiated immunization-related information to which patients are exposed.

Communication techniques for overcoming misinformation about vaccines

Motivational interviewing (MI) is an effective technique used by providers to communicate with patients who are reluctant or indecisive about vaccination. MI is defined as an individualized method to communicate and enhance motivation to explore and resolve ambivalence and resistance to change.³² Historically, MI has been used by psychologists to help patients with drug use disorders, but it is now being applied in multiple health care settings and to multiple patient populations.³³ Various MI techniques have been described, but these general approaches to interviewing can enhance a pharmacist’s ability to effectively communicate with patients³³ :

• Consider the patient’s perspective
• Exhibit empathy (especially in the face of resistance)
• Develop discrepancy
• Ask for permission to share information
• Reflect for patient feedback after providing information

Pharmacists can effectively advocate for influenza immunization by using MI techniques to communicate about immunizations with their patients. MI is one way to provide patient-centered care by communicating with patients regarding their primary concerns. While the instinct of a health care professional may be to correct inaccuracies when presented by a patient (known as the “righting reflex”), this response is likely to encourage defensiveness from the patient.³³ In the face of resistance to vaccination, avoiding negative statements and emphasizing personal choice with empathy are more likely to positively impact patient decision-making than arguing about a tightly held belief by the patient. For example, for a parent concerned about vaccinating his or her child with a vaccine containing thimerosal despite its proven safety profile, a provider could offer a preservative-free (PF) influenza vaccine instead of trying to convince the patient to accept a multi-dose influenza vaccine. If a PF vaccine is not available, the provider should identify that the parent cares about the safety of the child and then develop discrepancy by discussing the risks of avoiding vaccination instead of arguing the lack of link between autism spectrum disorder (ASD) and thimerosal. Figure 3 provides a case study based on the same situation and includes examples of non-MI and MI communication.

INFLUENZA VACCINATION IN THE COMMUNITY PHARMACY

The number of vaccinations provided in community pharmacies continues to increase as pharmacists play a larger role in providing this crucial public health solution. Community pharmacies have been significant drivers of immunization rates in states where policy changes promoted pharmacist-provided immunizations.³⁴ Given the abundance of community pharmacies that serve as accessible options for patients to receive vaccinations, both pharmacists and pharmacy technicians can play significant roles in advocating, promoting, and providing immunizations—including participating in state immunization registries when possible. 

The role of pharmacists in immunization

The American Pharmacists Association defines the roles for pharmacists involved in immunizations: advocate, educator, and provider.³⁵ Regardless of state-specific regulations regarding immunizations, pharmacists can advocate for immunizations through patient engagement and public-facing signage as well as getting immunized themselves to set an example for patients. Pharmacists have significant opportunities to serve as educators given the proximity of community pharmacies to patients. Many resources are available to help pharmacists and other health care professionals educate the public about immunizations and vaccines; some resources are listed in Table 4.^36-39

Most importantly, pharmacists can select appropriate immunizations and immunize to the fullest extent allowed by state laws and regulations. All states in the U.S. allow pharmacists to immunize, at least under certain circumstances, and promote immunization by providing this important clinical service, which positively impacts patient care and improves public health.⁴⁰ Immunizations are an excellent example of a clinical service provided using the Pharmacists’ Patient Care Process defined by the Joint Commission of Pharmacy Practitioners.

The role of pharmacy technicians in immunization

Pharmacy technicians play a significant role in pharmacy-administered immunizations. In addition to serving as advocates, pharmacy technicians can facilitate documentation and insurance billing while serving as the front-line representative of the pharmacy and communicating with patients.⁴¹ Technicians should obtain training and certification in cardiopulmonary resuscitation to increase awareness of and preparedness for adverse events related to immunizations and decrease the risks of serious consequences if such events should occur.⁴²

The body of evidence supporting pharmacy technician vaccine administration is growing and, in 2017, a pharmacy technician administered the first influenza vaccine allowed by law in the U.S.⁴³ Given appropriate regulation and education for patient safety, it is likely that the role of the pharmacy technician will continue to increase not only as an advocate but also as a provider of immunizations.

CONCLUSION

The influenza virus significantly impacts public health, but consistent vaccination remains the most effective method of prevention against the burden of a highly infectious disease, particularly for children and the elderly—populations at higher risk of complications related to influenza. Patients older than 6 months of age without a valid contraindication should receive at least one influenza vaccination annually including any age appropriate vaccine.¹⁴ Pharmacists and pharmacy technicians can play a significant role in public health by adhering to the most up-to-date vaccination recommendations and continue to help maintain public health by preventing the spread of the highly contagious influenza virus.

REFERENCES

1. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12(1):9-14.
2. Centers for Disease Control and Prevention. Overview of influenza surveillance in the United States. https://www.cdc.gov/flu/weekly/overview.htm. Updated October 19, 2018. Accessed September 27, 2019.
3. World Health Organization. Influenza: FluNet. http://www.who.int/influenza/gisrs_laboratory/flunet/en/. Updated September 16, 2019. Accessed September 30, 2019.
4. Centers for Disease Control and Prevention. Summary of the 2017-2018 Influenza Season. https://www.cdc.gov/flu/about/season/flu-season-2017-2018.htm. Updated September 5, 2019. Accessed September 27, 2019.
5. Flannery B, Reynolds SB, Blanton L, et al. Influenza vaccine effectiveness against pediatric deaths: 2010-2014. 2017;139(5).
6. Arriola CS, Garg S, Anderson EJ, et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. Clin Infect Dis. 2017;65(8):1289-1297.
7. Chapter 12: Influenza. In: Hamborskey J, Kroger A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-preventable Diseases. 13^th Washington, DC: Public Health Foundation; 2015. https://www.cdc.gov/vaccines/pubs/pinkbook/flu.html. Accessed September 30, 2019.
8. Lesson 1: Introduction to epidemiology: In: Principles of Epidemiology in Public Health Practice. 3^rd Atlanta, GA: Centers for Disease Control and Prevention; 2012. https://www.cdc.gov/csels/dsepd/ss1978/lesson1/section11.html. Accessed September 30, 2019.
9. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-695.
10. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006;12(1):15-22.
11. Viboud C, Simonsen L, Fuentes R, et al. Global mortality impact of the 1957-1959 influenza pandemic. J Infect Dis. 2016;213(5):738-745.
12. Viboud C, Grais RF, Lafont BA, et al. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect Dis. 2005;192(2):233-248.
13. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12(9):1085-1094.
14. Grohskopf LA, Alyanak E, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season. MMWR Recomm Rep 2019;68(No. RR-3):1–21.DOI: http://dx.doi.org/10.15585/mmwr.rr6803a1
15. S. Food and Drug Administration. FDA's Critical Role in Ensuring Supply of Influenza Vaccine. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm336267.htm. Updated March 1, 2019. Accessed September 30, 2019.
16. Centers for Disease Control and Prevention. Cell-Based Flu Vaccines. https://www.cdc.gov/flu/prevent/cell-based.htm. Updated September 5, 2019. Accessed October 8, 2019.
17. Centers for Disease Control and Prevention. Summary of Studies of Efficacy/Effectiveness of HD-IIV3, aIIV3, and RIV4 Compared with Unadjuvanted SD-IIVs against Laboratory-Confirmed Influenza Among Older Adults. https://www.cdc.gov/flu/professionals/acip/2019-2020/acip-table.htm. Updated August 28, 2018. Accessed September 30, 2019.
18. Grohskopf LA, Sokolow LZ, Fry AM, et al. Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) — United States, 2018–19 Influenza Season. Morb Mortal Wkly Rep. 2018;67(22):643–645.
19. Grohskopf LA, Olsen SJ, Sokolow LZ, et al; Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(32):691-697.
20. Chung JR, Flannery B, Thompson MG, et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics. 2016;137(2):e20153279.
21. Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Supply for the U.S. 2019-2020 Influenza Season. https://www.cdc.gov/flu/prevent/vaxsupply.htm. Updated August 23, 2018. Accessed September 30, 2019.
22. Sokolow LZ, Naleway AL, Li DK, et al. Severity of influenza and noninfluenza acute respiratory illness among pregnant women, 2010-2012. Am J Obstet Gynecol. 2015;212(2):202.e1-11.
23. Benowitz I, Esposito DB, Gracey KD, et al. Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis. 2010;51(12):1355-1361.
24. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54(10):1427-1436.
25. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194(8):1032-1039.
26. Mullooly JP, Bridges CB, Thompson WW, et al; Vaccine Safety Datalink Adult Working Group. Influenza- and RSV-associated hospitalizations among adults. Vaccine. 2007;25(5):846-855.
27. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. Vaccine. 2010;28(23):3929-3935.
28. Belongia EA, Sundaram ME, McClure DL, et al. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. 2015;33(1):246-251.
29. Destefano F, Price CS, Weintraub ES. Increasing exposure to antibody-stimulating proteins and polysaccharides in vaccines is not associated with risk of autism. J Pediatr. 2013;163(2):561-567.
30. Salathé M, Khandelwal S. Assessing vaccination sentiments with online social media: implications for infectious disease dynamics and control. PLoS Comput Biol. 2011;7(10):e1002199.
31. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2^nd New York: The Guilford Press; 2002.
32. Berger BA, Villaume WA. Motivational Interviewing for Health Care Professionals: A Sensible Approach. Washington, DC: American Pharmacists Association; 2013.
33. Drozd EM, Miller L, Johnsrud M. Impact of pharmacist immunization authority on seasonal influenza immunization rates across states. Clin Ther. 2017;39(8):1563-1580.e17.
34. Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. J Am Pharm Assoc (2003). 2006;46(2):168-179.
35. Centers for Disease Control and Prevention. Provider resources for vaccine conversations with parents. https://www.cdc.gov/vaccines/hcp/conversations/. Updated November 30, 2015. Accessed September 27, 2019.
36. Immunization Action Coalition. Talking about vaccines. http://www.immunize.org/talking-about-vaccines/. Updated January 17, 2019. Accessed September 27, 2019.
37. Centers for Disease Control and Prevention. Parents’ guide to childhood immunizations. https://www.cdc.gov/vaccines/parents/tools/parents-guide/index.html. Updated October 26, 2015. Accessed September 27, 2019.
38. Parents of Kids with Infectious Diseases. PKIDS Online. http://www.pkids.org/. Accessed September 27, 2019.
39. Immunization Action Coalition. State information: states allowing pharmacists to vaccinate. http://www.immunize.org/laws/pharm.asp. Updated November 11, 2018. Accessed September 27, 2019.
40. Powers MF, Hohmeier KC. Pharmacy technicians and immunizations. J Pharm Tech. 2011;27(3):111-116.
41. McKeirnan KC, Frazier KR, Nguyen M, et al. Training pharmacy technicians to administer immunizations. J Am Pharm Assoc. 2018; 58(2):174-178.
42. Atkinson D, Adams A, Bright D. Should pharmacy technicians administer immunizations? Inov Pharm. 2017;8(3):Article 16.

Back to Top